Terns Pharmaceuticals, Inc.
TERNDelisted May 5, 2026- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001831363
Terns Pharmaceuticals, Inc. was delisted on May 5, 2026; its insiders filed their last Form 4 on May 5, 2026; 317 institutions reported holding it in 13F filings for Q1 2026, worth $6.56B in total; Soros Fund Management was the only superinvestor holding it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Terns Pharmaceuticals, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Terns Pharmaceuticals, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Fellows David A | Director | – | May 5, 2026 | 2 |
| Kindler Jeffrey B | Director | – | May 5, 2026 | 2 |
| Turner Heather D | Director | – | May 5, 2026 | 2 |
| Gengos Andrew | Chief Financial Officer | 0 | May 5, 2026 | 2 |
| Azelby Robert | Director | – | May 5, 2026 | 2 |
| Tripuraneni Radhika | Director | – | May 5, 2026 | 2 |
| Quigley Jill M. | Director | 0 | May 5, 2026 | 3 |
| Burroughs Amy L. | Chief Executive Officer | 0 | May 5, 2026 | 5 |
| Kuriakose Emil | Chief Medical Officer | 0 | May 5, 2026 | 5 |
| Lu Hongbo | Director | 476,190Indirect | Jun 12, 2025 | 0 |
| Jung Melita Sun | Chief Business Officer | 2,250 | Feb 3, 2025 | 0 |
| Vignola Mark J. | Chief Financial Officer | 74,752 | Jan 6, 2025 | 0 |
| OrbiMed Advisors LLC | Director, 10% Owner | 755,635Indirect | Jul 17, 2024 | 0 |
| OrbiMed Capital GP VII LLC | Director, 10% Owner | 755,635Indirect | Jul 17, 2024 | 0 |
| OrbiMed Genesis GP LLC | Director, 10% Owner | 755,635Indirect | Jul 17, 2024 | 0 |
| OrbiMed Asia GP III, L.P. | Director, 10% Owner | 755,635Indirect | Jul 17, 2024 | 0 |
| OrbiMed Advisors III Ltd | Director, 10% Owner | 755,635Indirect | Jul 17, 2024 | 0 |
| Gordon Carl L | Director, 10% Owner | 755,635Indirect | Jul 17, 2024 | 0 |
| Taylor Ann Elizabeth | Director | – | Jul 2, 2024 | 0 |
| Yoon Seokho Bryan | COO and General Counsel | 91,940 | Jun 4, 2024 | 0 |
| Vivo Capital Fund VIII, L.P. | 10% Owner | 268,573Indirect | Apr 3, 2024 | 0 |
| Vivo Capital VIII, LLC | 10% Owner | 268,573Indirect | Apr 3, 2024 | 0 |
| Vivo Capital Surplus Fund VIII, L.P. | 10% Owner | 268,573Indirect | Apr 3, 2024 | 0 |
| Vivo Opportunity, LLC | 10% Owner | 268,573Indirect | Apr 3, 2024 | 0 |
| Vivo Opportunity Fund Holdings, L.P. | 10% Owner | 268,573Indirect | Apr 3, 2024 | 0 |
| Quirk Erin | President, Head of R&D | 75,000 | Jan 25, 2024 | 0 |
| Sundaram Senthil Vel | Chief Executive Officer | 9,770 | Jun 2, 2023 | 0 |
| LAV Biosciences Fund V, L.P. | 10% Owner | 529,762Indirect | Nov 28, 2022 | 0 |
| Oriental Spring Venture Ltd | 10% Owner | 529,762Indirect | Nov 28, 2022 | 0 |
| Hopewell Resources Holdings Ltd | 10% Owner | 529,762Indirect | Nov 28, 2022 | 0 |
| LAV Aqua Ltd | 10% Owner | 529,762Indirect | Nov 28, 2022 | 0 |
| Russell Kerry Strong | Chief Medical Officer | – | Jul 6, 2022 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Aug 16, 2022 (view filing) | Aug 12-16 | 4 days | Lu HongboDirector | PPurchase | +2.62M | $2.66 | +$6.98M | +734.4%2.98M after | 3 lots |
| Aug 16, 2022 (view filing) | Aug 16 | Same day | Lu HongboDirector | PPurchase | +1.50M | $2.42 | +$3.63M | –1.50M after | Derivative |
| Jun 8, 2022 (view filing) | May 31 | 8 daysLate | Yoon Seokho BryanCOO and General Counsel | PPurchase | +7.66K | $1.47 | +$11.3K | New position7.66K after | |
| Jun 8, 2022 (view filing) | May 31 | 8 daysLate | Vignola Mark J.Chief Financial Officer | PPurchase | +7.66K | $1.47 | +$11.3K | New position7.66K after | |
| Jun 8, 2022 (view filing) | May 31 | 8 daysLate | Sundaram Senthil VelChief Executive Officer | PPurchase | +7.66K | $1.47 | +$11.3K | New position7.66K after |